Crizanlizumab Completed Phase 2 Trials for Coronavirus Disease 2019 (COVID‑19) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04435184Crizanlizumab for Treating COVID-19 Vasculopathy